A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19

IF 0.8 Q4 HEMATOLOGY

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-09-21 DOI:10.1016/j.lrr.2026.100609

Priyanka Mehta, Tomas Skacel, Stefan Faderl, Roderick Murphy, Saemi Park, Abin Thomas, Sean Johnson, Alex Legg

{"title":"A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19","authors":"Priyanka Mehta, Tomas Skacel, Stefan Faderl, Roderick Murphy, Saemi Park, Abin Thomas, Sean Johnson, Alex Legg","doi":"10.1016/j.lrr.2026.100609","DOIUrl":null,"url":null,"abstract":"<div><div>CPX-351 improves outcomes for patients with secondary acute myeloid leukemia, but evidence of its use in high-risk myelodysplastic syndromes (MDS) is limited. This exploratory subgroup analysis of the randomized, controlled, open-label, phase 3 study—UK NCRI AML19—compared outcomes with CPX-351 versus FLAG-Ida in patients with high-risk MDS, to provide insights into the potential role of CPX-351 in this population. A total of 57 patients were included (CPX-351, n = 34; FLAG-Ida, n = 23). Compared with FLAG-Ida, CPX-351 prolonged median overall survival (OS; 17.8 vs 10.8 months) and median relapse-free survival (19.1 vs 7 months). Hematopoietic cell transplantation (HCT) rate was 59% and 52% for CPX-351 and FLAG-Ida, respectively. Median OS post-HCT was longer with CPX-351 than FLAG-Ida (22.3 vs 11.6 months). CPX-351 had a lower rate of serious adverse events than FLAG-Ida (9%vs 61%). These findings suggest that CPX-351 may be a promising frontline treatment option for high-risk MDS, and warrant confirmation in prospective studies.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100609"},"PeriodicalIF":0.8000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221304892600049X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

CPX-351 improves outcomes for patients with secondary acute myeloid leukemia, but evidence of its use in high-risk myelodysplastic syndromes (MDS) is limited. This exploratory subgroup analysis of the randomized, controlled, open-label, phase 3 study—UK NCRI AML19—compared outcomes with CPX-351 versus FLAG-Ida in patients with high-risk MDS, to provide insights into the potential role of CPX-351 in this population. A total of 57 patients were included (CPX-351, n = 34; FLAG-Ida, n = 23). Compared with FLAG-Ida, CPX-351 prolonged median overall survival (OS; 17.8 vs 10.8 months) and median relapse-free survival (19.1 vs 7 months). Hematopoietic cell transplantation (HCT) rate was 59% and 52% for CPX-351 and FLAG-Ida, respectively. Median OS post-HCT was longer with CPX-351 than FLAG-Ida (22.3 vs 11.6 months). CPX-351 had a lower rate of serious adverse events than FLAG-Ida (9%vs 61%). These findings suggest that CPX-351 may be a promising frontline treatment option for high-risk MDS, and warrant confirmation in prospective studies.

查看原文本刊更多论文

CPX-351和FLAG-Ida在高危骨髓增生异常综合征中的随机比较：英国NCRI AML19的亚组分析

CPX-351改善了继发性急性髓系白血病患者的预后，但其用于高危骨髓增生异常综合征（MDS）的证据有限。这项随机、对照、开放标签的3期研究-英国NCRI aml19的探索性亚组分析比较了CPX-351与FLAG-Ida在高危MDS患者中的结果，以深入了解CPX-351在这一人群中的潜在作用。共纳入57例患者（CPX-351, n = 34; FLAG-Ida, n = 23）。与FLAG-Ida相比，CPX-351延长了中位总生存期（OS； 17.8个月vs 10.8个月）和中位无复发生存期（19.1个月vs 7个月）。CPX-351和FLAG-Ida的造血细胞移植率分别为59%和52%。CPX-351组hct后的中位OS时间长于FLAG-Ida组（22.3个月vs 11.6个月）。CPX-351的严重不良事件发生率低于FLAG-Ida （9%vs 61%）。这些发现表明，CPX-351可能是高风险MDS的一线治疗选择，值得在前瞻性研究中得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊